NCT06266923

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of SPH6516 Tablets in Subjects With Advanced Solid Tumors.

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	SPH6516 tablets	SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle

Timeline

• Start date: 2022-01-20
• Primary completion: 2023-04-20
• Completion: 2023-11-01
• First posted: 2024-02-20
• Last updated: 2024-02-20

Locations

2 sites across 1 country: China